and licensed by Eli Lilly in 2018
Patients with a personal or family history of thyroid cancer or multiple endocrine neoplasia type 2 are typically excluded from GLP-1 treatment due to safety concerns
For example, studies published in journals like National Institutes of Health research on GLP-1 highlight how these medications alter central appetite regulation
Jennifer Linge will serve as one of three experts during an important session regarding the effects of GLP-1-based treatments on muscle health in cardiometabolic diseases, titled Great Debate: do GLP-1 analogues/GLP-1 receptor agonists (GLP-1RAs) worsen muscle loss in cardiometabolic disease? The goal of the session, as outlined by the organizers, is to understand the mechanism and clinical role of GLP-1 receptor agonists in cardiometabolic disease
If you, or someone you know, is in crisis or needs immediate assistance, please call 911 immediately
The relationship between obesity and ulcerative colitis is complex
